-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Neutral on Bristol-Myers Squibb, Raises Price Target to $64

Benzinga·02/06/2026 18:43:28
Listen to the news
Citigroup analyst Geoff Meacham maintains Bristol-Myers Squibb (NYSE:BMY) with a Neutral and raises the price target from $60 to $64.